Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (81-90 of 284) with videos related to

Pageof 29
Sort By:
European Journal of Radiology Open|April 16, 2019
Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcomeTetsuro Araki, Suzanne E Dahlberg, Tomoyuki Hida, et al.
The Oncologist|January 31, 2019
M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical OutcomeHyesun Park, Suzanne E Dahlberg, Christine A Lydon, et al.
European Journal of Radiology Open|October 26, 2020
Tumor volume dynamics and tumor growth rate in <i>ALK</i>-rearranged advanced non-small-cell lung cancer treated with crizotinibMizuki Nishino, Tomoyuki Hida, Sasha Kravets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2010
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibStephanie Heon, Beow Y Yeap, Gregory J Britt, et al.
Cancer|June 22, 2011
Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancerMary E Cooley, Karen M Emmons, Robert Haddad, et al.
Cancer|May 24, 2022
State legislative trends related to biomarker testingGelareh Sadigh, Hilary Gee Goeckner, Ella A Kazerooni, et al.
Cancer|February 8, 2007
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancerLeena Gandhi, Matthew W Harding, Marcus Neubauer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKIMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
AJR. American Journal of Roentgenology|June 25, 2013
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0Mizuki Nishino, Stephanie Cardarella, David M Jackman, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 30, 2012
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumabMizuki Nishino, Sarah K Cryer, Yuka Okajima, et al.
Pageof 29

Showing results (81-90 of 284) with videos related to

Sort By:
Pageof 29
European Journal of Radiology Open|April 16, 2019
Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcomeTetsuro Araki, Suzanne E Dahlberg, Tomoyuki Hida, et al.
The Oncologist|January 31, 2019
M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical OutcomeHyesun Park, Suzanne E Dahlberg, Christine A Lydon, et al.
European Journal of Radiology Open|October 26, 2020
Tumor volume dynamics and tumor growth rate in <i>ALK</i>-rearranged advanced non-small-cell lung cancer treated with crizotinibMizuki Nishino, Tomoyuki Hida, Sasha Kravets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2010
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibStephanie Heon, Beow Y Yeap, Gregory J Britt, et al.
Cancer|June 22, 2011
Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancerMary E Cooley, Karen M Emmons, Robert Haddad, et al.
Cancer|May 24, 2022
State legislative trends related to biomarker testingGelareh Sadigh, Hilary Gee Goeckner, Ella A Kazerooni, et al.
Cancer|February 8, 2007
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancerLeena Gandhi, Matthew W Harding, Marcus Neubauer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKIMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
AJR. American Journal of Roentgenology|June 25, 2013
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0Mizuki Nishino, Stephanie Cardarella, David M Jackman, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 30, 2012
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumabMizuki Nishino, Sarah K Cryer, Yuka Okajima, et al.
Pageof 29